SandpiperSandpiperSandpiperSandpiper
  • Expertise
  • People
  • Careers
  • News & Insights
  • Contact
  • Events
Navigating Business Opportunities in China
Outcomes of China National People’s Congress 2022 (Part 1) – Uncertainties & Government Strategies
Outcomes of China National People’s Congress 2022 (Part 2) – Business Opportunities
Outcomes of China National People’s Congress 2022 (Part 2) – Business Opportunities

Is it Time for Healthcare Organisations to Drive Social Impact?

Categories
  • Environmental, Social and Governance (ESG)
  • Health
Tags
  • health equity
Is it Time for Healthcare Organizations to Drive Social Impact?
News & insights

Is it Time for Healthcare Organisations to Drive Social Impact?

April 2022

Is it Time for Healthcare Organisations to Drive Social Impact?

by Tseng Yi Ying, Account Manager based in Sandpiper Singapore. Yi Ying has broad experience in healthcare communication, patient advocacy, research, stakeholder engagement and content development.


Good health is about more than just genetics. Where we are born can influence not just our likelihood of illness but also our access to treatment. Poorer communities tend to face more socio-economic disadvantages that put them at greater risk of poor health, while also facing barriers to healthcare such as high out-of-pocket expenses and poor medical coverage.

In short, there is a strong link between health and wealth. Therefore, we need to address the social determinants of health, not just treat disease. This requires a shift from health equality to health equity: resources and interventions should focus on the specific needs of individual communities, rather than one approach being applied across entire countries.

For this reason, patient-centric pharmaceutical companies put CSR (Corporate Social Responsibility) at the heart of their activities. However, the concept of CSR continues to evolve. It is no longer just about fair trade or charitable donations. Now, good corporate citizenship is a more holistic concept involving environmental, social, and governance (ESG) pillars.

Whilst ESG initiatives like these have become more popular in Asia-Pacific over the last decade, with companies in Hong Kong, Taiwan, and South Korea being some of the earliest adopters, we most often hear about environmental and governance initiatives and less about social activities.

But we know that socio-economic factors have a profound effect on population health. Therefore, there are significant opportunities for life science and pharmaceutical companies to drive social impact in the region and – in doing so – achieve more equitable health outcomes.

Socio-economic factors have a profound effect on population health.

There are significant opportunities for life science and pharmaceutical companies to drive social impact in the region and – in doing so – achieve more equitable health outcomes.

How COVID-19 amplified the need for health equity strategies

How COVID-19 amplified the need for health equity strategies

The COVID-19 pandemic shone a spotlight on the social determinants of health. In Asia-Pacific, less developed countries struggled to access, store, and transport vaccines. This led to longer lockdowns, higher caseloads, and poorer outcomes.

Meanwhile, more developed societies – with greater financial resources, medical facilities, and logistical infrastructure – were able to procure and provide doses at speed and scale.

This is how countries like Thailand have been able to vaccinate three quarters (75.6 per cent) of their population. To put that in perspective: it is almost double the 39.3 per cent vaccination rate in next-door Myanmar. These inequalities have prompted pharmaceutical and life science companies to re-evaluate their strategic purpose and ESG mission.

Tackling the social determinants of health

Tackling the social determinants of health

For instance, AstraZeneca made the decision to sell its vaccine at cost-price to poorer countries for as long as the WHO defined COVID-19 as a global pandemic. Meanwhile, others in the field are also taking steps to address the impact of social injustice on health outcomes, including but not limited to diversification in clinical trials to ensure that under-served communities at heightened risk of disease are better able to benefit from new and innovative treatments in the future.

Life science and pharmaceutical companies have also taken other initiatives to promote health equity, such as:

  • Building cross-sector consensus through summits with representatives of governments, the health sector, academia, charities, and other stakeholders to develop new ideas to address challenges in providing access to drugs.
  • Bringing together patient groups and business leaders to discuss strategies to address the root causes of health inequalities.
  • Creating health innovation challenges to give under-represented communities the chance to share their ideas about how to improve access to treatment and tackle the healthcare issues that affect them.
  • Funding scholarships to attract the brightest and best from all backgrounds to ensure a more diverse workforce in the life sciences and pharmaceutical sectors.

However, to be effective, these interventions need to recognize and respond to the real challenges of communities on the ground. There is no one-size-fits-all approach. So, what works in one area might not work in another. In our next article, we will dive deeper into health equity in Asia-Pacific and discuss some of the strategies that pharmaceutical and life science companies can use to make a tangible impact in communities across the region.


You may also like:

Navigating the era of Healthcare communications strategy
Sandpiper Healthcare Tracker - health as a priority and its impact on comms
Sandpiper launches Healthcare Consultancy - Sandpiper Health


Share

BEIJING
Suite 1105, Full Tower,
No. 9 Middle East 3rd Ring Road,
Chaoyang District, Beijing, PRC

北京市朝阳区东三环中路9号
富尔大厦1105室

+ 86 10 8591 0056
beijing@sandpipercomms.com

HONG KONG
21/F, The Workst@tion,
43 Lyndhurst Terrace, Central,
Hong Kong

香港中環擺花街43號
The Workst@tion 21樓

+852 3114 6339
hongkong@sandpipercomms.com

NEW ZEALAND
The Hive 2/200,
Market Street North, Hawkes Bay,
New Zealand

+64 21084 40939
newzealand@sandpipercomms.com

SHANGHAI
No 1229 Century Avenue, 6/F, Tower 1.
Century Metropolis.
Pudong New District. Shanghai. 200122

世纪大道1229号, 世纪大都会6层,
浦东新区, 上海市, 上海市, 200122

+86 15507577095
shanghai@sandpipercomms.com

SINGAPORE
#21-02, Prudential Tower, 30 Cecil Street,
Raffles Place, Singapore, 049712

+65 6592 2883
singapore@sandpipercomms.com

SYDNEY
Gateway Tower,
36/1 Macquarie Place, Sydney
NSW 2000, Australia

+612 9098 4321
sydney@sandpipercomms.com

OUR AFFILIATE NETWORK
Bangkok
Berlin
Brusels
Dubai
Frankfurt
Hanoi
Ho Chi Minh City
Jakarta
Kuala Lumpur
London
Manila
Mumbai
New York
Paris
San Francisco
Seoul
Taipei
Tokyo
Yangon
Zurich
logo

OUR AFFILIATE NETWORK
Bangkok Berlin Brussels Dubai Frankfurt Hanoi Ho Chi Minh City Jakarta Kuala Lumpur London  
Manila Mumbai New York Paris San Francisco Seoul Taipei Tokyo Yangon Zurich

Copyright © Sandpiper Terms of Use Privacy Policy